Caicun Zhou
Shanghai East Hospital
Emerging Leaders
#64212 pts
Current Leaders
#1366 pts
All-Time Leaders
#3,84312 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2024. 11 trials as lead/chair. How it works →
Trials led — by scientific impact
A Phase Ib/II, Open, Dose-escalation and Expansion Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors
Phase 2RecruitingL & L Bio Co., Ltd., Ningbo, China
5
impact
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics and Preliminary Efficacy of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
Phase 1RecruitingSichuan Baili Pharmaceutical Co., Ltd.
2
impact
A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kinase Inhibitor (Crizotinib) in TKI-Naïve Patients With ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRUST-III)
Phase 3RecruitingNuvation Bio Inc.
2
impact
A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2RecruitingSichuan Baili Pharmaceutical Co., Ltd.
1
impact
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
Phase 2RecruitingSichuan Baili Pharmaceutical Co., Ltd.
1
impact
A Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of AXL Inhibitor FC084CSA Tablets in Combination With Tislelizumab in the Treatment of Advanced Malignant Solid Tumors
Phase 2RecruitingFindCure Biosciences (ZhongShan) Co., Ltd.
0
impact
A Multicenter, Open-lable, Randomized Phase III Study of PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
Phase 3ActiveBiotheus Inc.
0
impact
A Phase I/II Multicenter, Open Label, Single-arm Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of WSD0922-FU in the Treatment of Advanced Non-small Cell Lung Cancer
Phase 2RecruitingWayshine Biopharm, Inc.
0
impact
An Open-label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics or Preliminary Efficacy and Antitumor Activity of GNC-077 Multi-specific Antibody Injection in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Other Solid Tumors
Phase 1RecruitingSichuan Baili Pharmaceutical Co., Ltd.
0
impact
A Multicenter Prospective Cohort Study of the Patient-Reported Outcomes in ALK Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China
N/ANot Yet RecruitingShanghai East Hospital
0
impact